It is early and Biopure Corp., a small biopharmaceutical firm with no sales revenues in its ten-year history, has just received government approval to. Biopure enters the field of blood substitutes: Human market – Hemopure; Veterinary market – Oxyglobin; Oxyglobin already received final FDA. Biopure Corp. case study. John T. Gourville. Save; Share. Save; Share. Format. PDF Hardcopy Black & White. Format. PDF, Hardcopy.

Author: Makasa Golmaran
Country: Solomon Islands
Language: English (Spanish)
Genre: Politics
Published (Last): 7 December 2015
Pages: 385
PDF File Size: 15.64 Mb
ePub File Size: 9.3 Mb
ISBN: 415-1-36244-865-2
Downloads: 15861
Price: Free* [*Free Regsitration Required]
Uploader: Nirr

If we set up a sales team with 50 staff, each staff will be responsible for 30 — 45 in one year. Slazenger had been the official and only supplier of tennis balls since So we think this is negative biopurs.

In response to the timing of approval for these xorporation products, there has been a long-running debate within Biopure as how to proceed with Oxyglobin. Strategic Marketing Management Name: Oxyglobin is the first new blood substitute for the veterinary market and is ready for consumer use.

Biopure Corporation Case 1. About the Author John T. Click here to sign up. Instead, distributors work for many manufacturers and they will not be fully committed to Oxyglobin. Log In Sign Up. Instead of making a contract with one of the distributors, Biopure should consider of distributing Oxyglobin by using its salesforces.

We cannot ignore the presence here of some inherentalthough we cannot directly say the pricing of pet products determined that people use the same type of product price must be to what extent.


Biopure Corp.

For the price of acceptance will have a direct impact. Cite View Details Educators. It is very likely that the numbers will rise by the year of Oxyglobin release.

The raw material will cost 1. What is the market potential for Oxyglobin in the animal market and Hemopure in the human market? This task is easier for biopuer classes of new products than for others.

A virtually identical product for the human market, Biiopure, is in the final stages of testing by Biopure and is expected to gain approval within one to two years. Cite View Details Educators Related. Finance Globalization Health Care. We noted that our pricing for Oxyglobin probably should be between the second question we have detailed presentation of this specific product pricing principles and price. How might the presence of Oxyglobin be an asset or liability to Hemopure?

Widely regarded as the most prestigious professional tennis tournament in the world and contested each year over two weeks in late June and early July, Wimbledon, in many ways, had changed little over the years.

Cite View Details Educators Purchase. So we can choose to price based on critical case. The coefficient is generally between 0. And we cannot let the price difference to be unreasonably high since there is no essential difference between two products. Business and Environment Business History Entrepreneurship.

Ted Jacobs, vice president for Human Clinical Trials, is concerned about creating an unrealistic price expectation for Hemopure by marketing Oxyglobin before Hemopure. Cass motivation behind the push into digital was one of communicating and engaging with fans and potential fans around the world, as noted by Richard Lewis, Chief Executive of the AELTC.


Oxyglobin would create an unrealistic price expectation for Hemopure if released first.

Help Center Find new research papers in: I believe that this is a big opportunity for Biopure to enter the veterinary market because Oxyglobin has already passed an FDA — approval process specific to the veterinary market. Once Oxyglobin achieves its purpose for animals and satisfies the veterinary doctors and pet owners, the success of this product will help Biopure to easily launch Hemopure and attract the human market. Enter the email address you signed up with and we’ll email you a reset link.

Also, we noted blood transfusion is mainly used in emergency cases instead of ordinary cases. Hemopure is another bioppure blood substitute for the human market and it will take two years to launch the product from now on.

I think that launching Oxyglobin has many benefits for the company. We have to ensure the sales team has been well trained and can teach veterinarians how to properly use the product.

Business case Biopure by Simone Huygens on Prezi

We also have to cover the selling expenses. He can only estimate these price points based on the market price.

Due to Rejection Due to Expiration Total: Skip to main content. What are the reasons for and against launching Oxyglobin?